112 citations
- Bristol-Myers Squibb (Germany)DE2 papers
- AbbVie (United States)US1 paper
- Bristol-Myers Squibb (Belgium)BE1 paper
- Celgene (United States)US1 paper
- Eli Lilly (United States)US1 paper
- Genentech1 paper
- Janssen Research & Development (United States)US1 paper
- Korea Advanced Institute of Science and TechnologyKR1 paper
- Merck & Co., Inc., Rahway, NJ, USA (United States)US1 paper
- Peking UniversityCN1 paper
- Pfizer (United States)US1 paper
- Roche (United States)US1 paper
7 papers
Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology
Hao Sun, Hsin-Yu Lin, Jieqi Tu +2
Traditional phase I dose finding cancer clinical trial designs aim to determine the maximum tolerated dose (MTD) of the investigational cytotoxic agent based on a single toxicity o…
A Bayesian hierarchical mixture cure modelling framework to utilize multiple survival datasets for long-term survivorship estimates: A case study from previously untreated metastatic melanoma
Nathan Green, Murat Kurt, Andriy Moshyk +2
Time to an event of interest over a lifetime is a central measure of the clinical benefit of an intervention used in a health technology assessment (HTA). Within the same trial, mu…
Robust Estimation of Sparse Precision Matrix using Adaptive Weighted Graphical Lasso Approach
Peng Tang, Huijing Jiang, Heeyoung Kim +1
Estimation of a precision matrix (i.e., inverse covariance matrix) is widely used to exploit conditional independence among continuous variables. The influence of abnormal observat…
A practical Response Adaptive Block Randomization (RABR) design with analytic type I error protection
Tianyu Zhan, Lu Cui, Ziqian Geng +3
Response adaptive randomization (RAR) is appealing from methodological, ethical, and pragmatic perspectives in the sense that subjects are more likely to be randomized to better pe…
Alternative Analysis Methods for Time to Event Endpoints under Non-proportional Hazards: A Comparative Analysis
Ray S. Lin, Ji Lin, Satrajit Roychoudhury +16
The log-rank test is most powerful under proportional hazards (PH). In practice, non-PH patterns are often observed in clinical trials, such as in immuno-oncology; therefore, alter…
Estimation of Optimal Individualized Treatment Rules Using a Covariate-Specific Treatment Effect Curve with High-dimensional Covariates
Wenchuan Guo, Xiao-hua Zhou, Shujie Ma
With a large number of baseline covariates, we propose a new semi-parametric modeling strategy for heterogeneous treatment effect estimation and individualized treatment selection,…